237 related articles for article (PubMed ID: 11464113)
21. [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder].
Leng J; Zhang Y; Yao X; Wen K
Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):40-3. PubMed ID: 11831985
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
23. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
Schlichtholz B; Presler M; Matuszewski M
Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
[TBL] [Abstract][Full Text] [Related]
24. p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage.
Skopelitou A; Hadjiyannakis M; Dimopoulos D; Kamina S; Krikoni O; Alexopoulou V; Rigas C; Agnantis NJ
Eur Urol; 1997; 31(4):464-71. PubMed ID: 9187909
[TBL] [Abstract][Full Text] [Related]
25. bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection.
Ye D; Li H; Qian S; Sun Y; Zheng J; Ma Y
J Urol; 1998 Dec; 160(6 Pt 1):2025-8; discussion 2029. PubMed ID: 9817315
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of p53 nuclear accumulation in low- and high-grade (WHO/ISUP classification) transitional papillary carcinomas of the bladder for tumor recurrence and progression.
Vardar E; Gunlusoy B; Minareci S; Postaci H; Ayder AR
Urol Int; 2006; 77(1):27-33. PubMed ID: 16825812
[TBL] [Abstract][Full Text] [Related]
27. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki67 index.
Wright C; Thomas D; Mellon K; Neal DE; Horne CH
Br J Urol; 1995 Feb; 75(2):173-9. PubMed ID: 7850321
[TBL] [Abstract][Full Text] [Related]
28. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder.
Glick SH; Howell LP; White RW
J Urol; 1996 May; 155(5):1754-7. PubMed ID: 8627878
[TBL] [Abstract][Full Text] [Related]
29. Apoptosis in transitional cell carcinoma of bladder and its relation to proliferation and expression of p53 and bcl-2.
Amirghofran Z; Monabati A; Khezri A; Malek-Hosseini Z
Pathol Oncol Res; 2004; 10(3):154-8. PubMed ID: 15448751
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of p53 protein accumulation in stage pT1 transitional cell carcinoma of the bladder.
Toktaş G; Türkeri LN; Unlüer E; Atuğ F; Murat C; Ozveren B; Calişkan M; Akdaş A
Int Urol Nephrol; 1999; 31(4):437-41. PubMed ID: 10668937
[TBL] [Abstract][Full Text] [Related]
32. Variable Bcl-2 phenotype in benign and malignant lesions of urothelium.
Bilim VN; Tomita Y; Kawasaki T; Takeda M; Takahashi K
Cancer Lett; 1998 Jun; 128(1):87-92. PubMed ID: 9652797
[TBL] [Abstract][Full Text] [Related]
33. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma.
Rodríguez-Alonso A; Pita-Fernández S; González-Carreró J; Nogueira-March JL
Eur Urol; 2002 Feb; 41(2):182-8; discussion 188-9. PubMed ID: 12074407
[TBL] [Abstract][Full Text] [Related]
34. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Liu L; Zhu D; Gao R; Guo H
Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
[TBL] [Abstract][Full Text] [Related]
36. The significance of p53 and bcl-2 overexpression and other prognostic factors in transitional cell carcinoma of the bladder.
Touloupidis S; Fatles G; Kalaitzis C; Giatromanolaki A; Sivridis E; Simopoulos K; Rombis V
Int Urol Nephrol; 2006; 38(2):231-6. PubMed ID: 16868688
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation.
Cheng HL; Trink B; Tzai TS; Liu HS; Chan SH; Ho CL; Sidransky D; Chow NH
J Clin Oncol; 2002 Mar; 20(6):1544-50. PubMed ID: 11896103
[TBL] [Abstract][Full Text] [Related]
38. Accumulation of nuclear p53 and tumor progression in bladder cancer.
Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
[TBL] [Abstract][Full Text] [Related]
39. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.
Dalbagni G; Parekh DJ; Ben-Porat L; Potenzoni M; Herr HW; Reuter VE
BJU Int; 2007 Feb; 99(2):281-5. PubMed ID: 17155984
[TBL] [Abstract][Full Text] [Related]
40. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder.
Hussain SA; Ganesan R; Hiller L; Cooke PW; Murray P; Young LS; James ND
Oncol Rep; 2003; 10(3):571-6. PubMed ID: 12684626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
